Form 4: ORIC Director Exercises Options, Boosts Stake

Oric Pharmaceuticals Director Lori Anne Kunkel exercised options to acquire 10,000 shares of common stock at $7.90 per share, increasing her direct ownership.

Summary

• Lori Anne Kunkel, a Director at Oric Pharmaceuticals, Inc. (ORIC), exercised stock options.
• The transaction, dated December 8, 2025, involved the acquisition of 10,000 shares of common stock.
• The exercise price for these shares was $7.90 per share.
• Following this transaction, Kunkel directly beneficially owns 84,200 shares of common stock.
• Concurrently, 10,000 stock options with an exercise price of $7.90 were disposed of (exercised).
• Kunkel now directly beneficially owns 15,600 derivative securities (stock options).
• The options vested on the earlier of June 12, 2025, or the business day prior to the next annual meeting of stockholders following the grant date, and expire on June 11, 2034.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The exercise of options by a director, particularly under a Rule 10b5-1 plan, is generally a neutral to slightly positive signal. It indicates a pre-planned increase in direct ownership, which can be interpreted as continued confidence in the company's value, especially if the exercise price is favorable relative to the market price.

Positives

• An insider, a Director, is scheduled to increase their direct ownership in the company, which can signal confidence in the company's future prospects, especially if the exercise price of $7.90 is below the market price at the time of exercise.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the future transaction date and option expiration.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects a director's personal investment decision within the biotechnology or pharmaceutical sector, where Oric Pharmaceuticals operates.

Related Party Transactions

• Lori Anne Kunkel, a Director of Oric Pharmaceuticals, Inc., engaged in an equity transaction with the company by exercising stock options.

Stakeholder Impact

• Shareholders: The transaction increases a director's direct ownership, which could be viewed as a positive signal of management's alignment with shareholder interests. It also slightly increases the number of outstanding shares, though the impact is minimal for 10,000 shares.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction where a director exercised stock options under a Rule 10b5-1 plan. While it indicates insider confidence, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Investors should 'hold' and continue to monitor broader company performance and market conditions.

Keywords

Oric Pharmaceuticals, ORIC, Form 4, Insider Transaction, Stock Option Exercise, Director, Lori Anne Kunkel, Beneficial Ownership, Equity Acquisition, Rule 10b5-1